Details for Patent: 6,821,987
✉ Email this page to a colleague
Which drugs does patent 6,821,987 protect, and when does it expire?
Patent 6,821,987 protects FOTIVDA and is included in one NDA.
This patent has thirty-six patent family members in twenty-three countries.
Summary for Patent: 6,821,987
| Title: | Quinoline derivatives and quinazoline derivatives having azolyl group |
| Abstract: | An object of the present invention is to provide compounds having potent antitumor activity. The compounds according to the present invention are compounds represented by formula (I) or pharmaceutically acceptable salts or solvates thereof: ##STR1## wherein X and Z represent CH or N; Y represents O or S; R.sup.1, R.sup.2, and R.sup.3 represent H, alkoxy or the like; R.sup.4 represents H; R.sup.5, R.sup.6, R.sup.7, and R.sup.8 represent H, halogen, alkoxy or the like; R.sup.9 and R.sup.10 represent H, alkyl or the like; and R.sup.11 represents optionally substituted azolyl. |
| Inventor(s): | Kubo; Kazuo (Takasaki, JP), Sakai; Teruyuki (Takasaki, JP), Nagao; Rika (Takasaki, JP), Fujiwara; Yasunari (Saitama, JP), Isoe; Toshiyuki (Takasaki, JP), Hasegawa; Kazumasa (Takasaki, JP) |
| Assignee: | Kirin Beer Kabushiki Kaisha (Tokyo-to, JP) |
| Application Number: | 10/132,473 |
|
Patent Claim Types: see list of patent claims |
Drugs Protected by US Patent 6,821,987
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aveo Pharms | FOTIVDA | tivozanib hydrochloride | CAPSULE;ORAL | 212904-001 | Mar 10, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | A METHOD OF TREATING ADULTS WITH RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC THERAPIES BY INHIBITING THE ANGIOGENESIS OF BLOOD VESSELS WITH A VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITOR | ⤷ Sign Up | ||
| Aveo Pharms | FOTIVDA | tivozanib hydrochloride | CAPSULE;ORAL | 212904-002 | Mar 10, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | A METHOD OF TREATING ADULTS WITH RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC THERAPIES BY INHIBITING THE ANGIOGENESIS OF BLOOD VESSELS WITH A VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITOR | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 6,821,987
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Japan | 2001-132775 | Apr 27, 2001 |
International Family Members for US Patent 6,821,987
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1382604 | ⤷ Sign Up | 300927 | Netherlands | ⤷ Sign Up |
| European Patent Office | 1382604 | ⤷ Sign Up | CA 2018 00007 | Denmark | ⤷ Sign Up |
| European Patent Office | 1382604 | ⤷ Sign Up | CR 2018 00007 | Denmark | ⤷ Sign Up |
| European Patent Office | 1382604 | ⤷ Sign Up | 2018C/008 | Belgium | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
